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Introduction: Our consortium aims to develop a novel ex vivo cell-based therapy to treat haemophilia A 
(HA) that should ultimately lead to improved patient quality of life. Blood outgrowth endothelial cells 
(BOECs), a production source of factor VIII (FVIII) will be isolated from HA patients and genetically 
corrected with a lentiviral vector (LV) encoding for functional FVIII. Corrected cells will be expanded to 
guarantee a long-lasting therapy or cure. The cells will be tested for safety, efficacy and endothelial 
characteristics and transplanted into a subcutaneously implanted medical device for sustained 
secretion of FVIII in NOD/SCID γ-null (NSG) HA mice for preclinical studies. All processes will be 
performed under Good Manufacturing Practice (GMP) conditions, to ensure safety and quality 
according to the highest standards. 
Material & Methods: BOECs were isolated from non-haemophilia donors’ and patients' blood. Cells 
were efficiently transduced by LVs containing the B domain deleted form of human FVIII under control 
of the Vascular Endothelial Cadherin promoter (VEC). BOECs were characterized by FACS for 
endothelial phenotype and FVIII evaluated by APTT and ELISA. Ten million LV-VEC.hFVIII-BOECs were 
transplanted intraperitoneally on cytodex 3 microcarrier beads in NSG-HA mice (n=3). In addition 
corrected BOECS from HA patients will be transplanted into the medical device in NSG-HA mice for 
optimization of sustained FVIII secretion.   
Results: The number of integrated LV copies/cell was ~3 for LV-VEC.hFVIII transduced cells, yielding in 
67% of cells expressing FVIII determined by FACS. We confirmed endothelial phenotype of corrected 
cells by FACS detecting endothelial specific markers. BOECs survived and secreted FVIII at therapeutic 
levels (with a peak of 15% FVIII activity) for up to 13 weeks in mice. 
Conclusion: With our strategy, we achieved secretion of functional FVIII at therapeutic levels up to 13 
weeks in NSG-HA mice. Furthermore, we established a GMP compliant process for isolation of BOECs 
and currently establishing GMP compliance for the LV-transduction and expansion of BOECs as well. 
Based on the results we will accomplish GMP compliance for the whole process chain, we plan to 
transplant GMP produced, autologous gene corrected and safe BOECs for future clinical testing in 
HA patients. 
 
